Patents by Inventor Harry C. Ledebur, Jr.

Harry C. Ledebur, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T-Cell Recepter (TCR) Targeting Therapies for Immune-Mediated Adverse Drug Reactions (ADRs) and Other Conditions
    Publication number: 20180298099
    Abstract: The present invention provides methods and compositions for treating immune mediated adverse drug reactions using anti-?? TCR antibodies and fragments thereof. The adverse drug reactions treated according to the invention include severe cutaneous adverse reactions, idiosyncratic liver injury, and idiopathic drug-induced liver disease. The invention also provides methods and compositions for treating conditions such as epidermolysis bullosa, pemphigus vulgaris, cutaneous T cell lymphoma, and Goodpasture syndrome where T cells play a significant role. Anti-? TCR antibodies used in the treatment methods of the invention include T10B9, MEDI-500 and TOL101.
    Type: Application
    Filed: September 16, 2016
    Publication date: October 18, 2018
    Inventor: Harry C. Ledebur, JR.
  • Plasmid encoding a modified steroid hormone
    Patent number: 6416998
    Abstract: The present invention provides mutated proteins of steroid hormone receptors. These mutated proteins are useful as gene medicines. In particular, these mutated proteins are useful for regulating expression of genes in gene therapy. In addition, the present invention provides plasmids encoding for the desired mutated steroid hormone receptor proteins, as well as cells transfected with those plasmids.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 9, 2002
    Assignees: Baylor College of Medicine, Valentis, Inc.
    Inventors: Bert W. O'Malley, Ming-Jer Tsai, Harry C. Ledebur, Jr., Joseph D. Kittle, Jr.